Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2009-10-18 Annual Report
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
Annual Report to shareholders 74 pages ?Kb
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT' and contains typical sections found in an annual report such as Chairman's Report, CEO's Report, Directors' Report, Auditor's Independence Declaration, Corporate Governance Statement, and detailed Financial Statements including Income Statement, Balance Sheet, Cash Flow Statement, Notes, Directors' Declaration, and Independent Audit Report. The content covers a full fiscal year with highlights, management discussion, and financial data. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement or summary. There is no indication that this is merely an announcement of the report or a certification document. Therefore, this document fits the definition of an Annual Report (10-K). FY 2009
2009-10-18 English
Additional Information to the Annual Report 2 pages ?Kb
Major Shareholding Notification Classification · 95% confidence The document provides detailed information about the distribution of shareholders, unmarketable parcels, the 20 largest shareholders, substantial shareholders, and voting rights as of a specific date (30 September 2009). It does not contain financial statements, management discussion, or audit information. It is a shareholder-related update focusing on shareholding structure and voting rights, which aligns with the category of Major Shareholding Notification (MRQ). The document length is short (2489 characters), and it is not an announcement of a report but a direct disclosure of shareholder data. Therefore, the best fit is Major Shareholding Notification (MRQ).
2009-10-18 English
LCT Reports Successful First Implant Of DIABECELL in NZ 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a company announcement from Living Cell Technologies Limited reporting the successful first implant of DIABECELL in New Zealand. It describes a clinical trial and provides background information about the product and the company. There are no financial statements, regulatory filings, or detailed financial data. The document is an announcement of a clinical milestone rather than a financial report, regulatory filing, or management discussion. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a general company announcement about a clinical trial progress, which is best classified under Regulatory Filings (RNS) as a miscellaneous announcement that does not fit other specific categories.
2009-10-06 English
Initial Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including unlisted options and their terms. The document is a formal notification of a director's personal share transactions or interests, which aligns with the definition of Director's Dealing filings. The document length is short and focused solely on director interests, with no financial statements or other report content. Therefore, it fits the category of Director's Dealing (DIRS).
2009-09-28 English
Initial Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including unlisted options held by a related party. The content focuses on disclosure of personal share transactions or interests by a company director. There is no financial performance data, report publication, or management discussion. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is short and specific to director interests, confirming it is not a broader report or announcement.
2009-09-28 English
Change of Director`s Interest Notice 4 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including number of shares and options held before and after the change, dates of changes, and nature of the changes. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades or director dealings. It is not an annual report, earnings release, or any other financial report. The document length is about 4910 characters, which is consistent with a detailed director's dealing notice. Therefore, the correct classification is Director's Dealing (DIRS).
2009-09-28 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.